Unconventional Capital: Alternative Financing Options in a Down-turned Market

4/16/2009

Corporate, Emerging Companies + Venture Capital, and Life Sciences

South San Francisco, CA

Stephen B. Thau

Stephen B. Thau

Speaking Engagement

Morrison & Foerster is an invited presenter at BayBio 2009, a one-day conference focusing on Northern California's strength in life sciences product development and commercialization.

With public capital markets frozen and venture capital becoming scarce, life sciences companies are increasingly turning to alternative sources of capital to finance their endeavors. Project-based financing can monetize a revenue stream to fund other programs, while government grants and private foundations can support innovative work with non-dilutive capital, and can also provide scientific validation and peer review. Of course, there are pitfalls to avoid with each of these as well. What are the pros and cons of alternative financing options for life sciences companies? This discussion delves into these issues and examines the "how-tos" of implementing strategies for accessing capital in a down-turned market.

Moderator:

Stephen B. Thau
Partner, Morrison & Foerster LLP

Panel Speakers:

Michael J. Eichberg
Associate Director, Business Development, Achaogen, Inc.

Guy Miller, MD, PhD
Chairman, Chief Executive Officer, Edison Pharmaceuticals

Patricia Olson
Director of Scientific Activities, California Institute for Regenerative Medicine

Michael S. Ostrach
Chief Business Officer and General Counsel, Dynavax Technologies Corporation

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2018 Morrison & Foerster LLP. All rights reserved.